|
| | 
|
 | |
        
|  |
 
|
| PS: The quotes after 2017-05-12 are still temporary and may have for that reason the Open values wrong until furter updates...
Change to Biogen Idec Inc. Static Chart |
 Biogen Idec Inc. - [Ticker: BIIB] |     | | Last Trade | 315.51 | Last Trade Time | 2017-11-01 - 19:35:00 | | Variation | +3.85 (+1.24%) | Open | 312.75 | | High | 319.95 | Low | 311.57 | | Volume | 1,047,609 | Average Volume (3m) | 0 | | Yield | | Bid / Ask | 315.47 x 300 - 315.59 x 200 | | Former Close | 311.66 | 52 Week Range | [0.00 - 0.00] | | PER | 0.00% | EPS | 0.00 | | Ex-Dividend Date | | Dividend Payment | | | Market Capitalization | 0 | 1 Year Price-Target | 0.00 | | Note: The data may have some minutes of delay. |
|
News about Biogen Idec Inc. [BIIB]: (ordered by relevance)
| | Where Biogen Stands With Analysts - Benzinga Benzinga
Biogen Alzheimer's Drug Shows Brain Swelling In 35% Of Patients Benzinga
Biogen Loses Bid To Revive Tecfidera Drug Patent: Bloomberg - Benzinga Benzinga
Sage Therapeutics - Biogen Share One Year Zuranolone 50mg Data In Depression Patients - Benzinga Benzinga
Is Biogen Inc (BIIB) a Stock to Watch After Losing -3.00% This Week? InvestorsObserver
Plasma Expanders Market: Rising number of surgeries is expected to drive the market BioSpace
Biogen (BIIB) Stock Rises After Reporting Positive Data in Phase 3 Alzheimer's Trial InvestorsObserver
Workable Strategic Report on Solid Tumors Treatment Market by Forecast to 2027 with Covered Top Companies like Abbott Laboratories Inc., Biogen Idec Incorporated, AstraZeneca Plc Medgadget
Will Biogen Stock Rise After The Recent 6% Fall? Forbes
Aduhelm's 'Blockbuster Potential' Is Underappreciated, Says Biogen Analyst - Benzinga Benzinga
UPDATE: Biogen Shares Halted Ahead Of FDA Decision On Co.'s Alzheimer's Candidate, Aducanumab Monday Benzinga
Biogen Stock To See Much Higher Levels After A 38% Rise Yesterday Forbes
Here?s Why Biogen Stock Can Offer Over 35% Gains Forbes
Expert Ratings For Biogen - Benzinga Benzinga
Biogen Drops Idec From Name Wall Street Journal
Biogen Idec Becomes Biogen Business Wire
Alzheimer's drug from Biogen wins US approval Financial Times
Biogen Stock: With Alzheimer's Treatment In FDA Court, Is BIIB Stock A Buy In January 2021? Investor's Business Daily
Biogen bats aside Aduhelm jitters with confident third quarter The Pharma Letter
Biogen Idec: A Great Company, But Not An Alpha Opportunity Seeking Alpha
Biogen/Samsung Approval of BYOOVIZ? | Goodwin - JDSupra JD Supra
How Biogen Idec Inc. Uses Materiality Assessments to... 3BL Media
Biogen Idec Stock Hits New 52-Week High (BIIB) TheStreet.com
Biogen launches new trial of Alzheimer's drug aducanumab McKnight's Long Term Care News
Biogen Idec (NASDAQ: BIIB) will add 100 workers in North Carolina's Research Triangle Park - Triangle Business Journal Triangle Business Journal
Why Biogen's Fortunes Hinge On Aducanumab Approval - Benzinga Benzinga
Biogen shares leap after ?substantial evidence? Alzheimer?s drug is effective Financial Times
Cipla receives final approval for generic version of Biogen IDEC Inc.'s Tecfidera® (Dimethyl Fumarate DR Capsules 120mg, 240mg and 120mg/240mg Starter Pack) PRNewswire
Baidu And Nvidia Lead The QQQ Lower Thursday - Benzinga Benzinga
Biogen Idec's Plegridy approved in Europe for relapsing-remitting multiple sclerosis The Pharma Letter
Biogen Idec's Strategy For Neurology RD Success Life Science Leader Magazine
Biogen Inc. (BIIB) Stock Price Today, Quote & News Seeking Alpha
Biogen Idec (BIIB) shifts Machelle Sanders from head of RTP manufacturing to lead multiple sclerosis development - Triangle Business Journal Triangle Business Journal
Biogen's Case For Aduhelm For Alzheimer's Seeking Alpha
Is Biogen Getting Desperate? Motley Fool
Subcutaneous Biologics Market Market to See Huge Growth by 2030 | Abbott Laboratories, Pfizer Inc., Genentech Inc., Novartis AG, Biogen Idec Medgadget
Biogen Idec to Acquire Stromedix Business Wire
Biogen Agrees to Pay $22 Million to Resolve Allegations that it Paid Kickbacks Through Two Co-Pay Foundations Department of Justice
Here?s what?s weighing down this biotech stock CNBC
Biogen Idec scores lung disease drug in $562.5M buyout of Stromedix FierceBiotech
Biogen Idec provides coach commuting for suburban workers Boston Globe
Biogen Idec Moves Aggressively, Advances Alzheimer Drug InTo Phase 3 Clinical Leader
Biogen Idec grabs Convergence, neuropathic pain portfolio in $675M buyout FierceBiotech
Quintiles and Biogen Idec Announce Comprehensive Clinical Development Partnership Business Wire
How Biogen Makes Money: Treatments for Neurological Disorders Investopedia
Biogen Idec Moving HQ Back to Cambridge, Constructing Two New Buildings at Kendall Square Xconomy
Trial hit may not be good enough for Sage and Biogen The Pharma Letter
Profits up, Biogen cuts 11% of global workforce Fortune
Biogen Idec. chief executive to retire - The Boston Globe Boston Globe
Biogen Idec and Samsung Bioepis Announce Agreement to Market Anti-TNF Biosimilar Product Candidates in Europe Business Wire
Biogen Idec Trading Higher on 1.7x Above-Average Volume (BIIB) - Benzinga Benzinga
Which Fund Has The Most To Gain From Biogen Idec? Benzinga
FDA Accepts Biogen's BLA for Alzheimer's Candidate Aducanumab Genetic Engineering & Biotechnology News
Biogen: Big Biotech Play Ready To Move Seeking Alpha
Exclusive: Biogen prices hemophilia drug on par with older therapies Reuters
Biogen Idec Set to Join the S&P 100; Keurig Green Mountain to Join the S&P 500; Changes to the S&P MidCap 400 and the S&P SmallCap 600 PR Newswire
UPDATED: Germany gives an initial 'no additional benefit' on Biogen Idec's Tecfidera FiercePharma
Biogen Idec, Atlas Venture Pump $17M into Ataxion Genetic Engineering News
Biogen Idec CEO Jim Mullen Stepping Down, After Tumultuous Year of Shareholder Activism Xconomy
Biogen CEO has 'mixed emotions' as he leaves company after 6 years CNBC
Ataxion Announces $17M Series A Financing from Atlas Venture and Biogen Idec Business Wire
Biogen to pay Forward Pharma $1.25 billion to protect MS drug Reuters
Classen Immunotherapies, Inc. v. Biogen IDEC (Fed. Cir. 2011) Patent Docs
Biogen Must Face FCA Suit Minus 17 State-Level Claims Law360
| For more news about Biogen Idec Inc. click here:
Biogen Idec Inc. News |
|
Website Width:
Background image: |
|  | |
|
|
